Beijing Watson Innovative Biotechnology

Beijing Watson Innovative Biotechnology is a specialized subsidiary of Walvax Biotechnology focused on the research, development, and industrialization of innovative mRNA-based vaccines and therapeutics. The company gained significant international attention for its collaboration with Abogen Biosciences and the Academy of Military Medical Sciences to develop AWcorna (ARCoV), China's first domestically developed mRNA COVID-19 vaccine to receive emergency use authorization. Beyond COVID-19, the company is leveraging its mRNA and lipid nanoparticle (LNP) delivery platforms to target a broad range of infectious diseases, including influenza and respiratory syncytial virus (RSV). Based in Beijing, the entity serves as a critical R&D hub for the parent company's transition toward next-generation vaccine technologies.